SEC Form 13F Information Table Summary
Business Context and Reporting Period
This filing is a Form 13F Information Table submitted by Carlyle Group Inc. for the reporting period ending June 30, 2023. The document discloses the company's holdings in equity securities as of the end of the quarter. It does not contain Carlyle Group's own financial performance metrics (revenue, profit, cash flow) but rather details its investment portfolio.
Key Financial Metrics and Portfolio Composition
The filing lists 26 distinct equity positions. The total value of reported holdings is not explicitly summed in the text, but individual position values are provided. Voting authority is primarily held solely by the manager.
| Issuer | Shares Held | Value (USD) | Voting Authority |
|---|---|---|---|
| ZoomInfo Technologies Inc | 36,662,469 | $930,860,088 | Sole |
| Quidelortho Corp | 12,460,183 | $1,032,450,763 | Sole |
| MKS Instrs Inc (Combined) | 3,482,732 | $376,483,329 | Sole |
| GDS Hldgs Ltd | 4,072,624 | $44,758,142 | Sole |
| Getty Images Holdings Inc | 9,976,300 | $48,684,344 | Sole |
| Vitru Ltd | 6,246,471 | $100,130,930 | Sole |
| Adicet Bio Inc | 2,115,385 | $5,119,232 | Sole |
| Other Positions | Various | Various | Sole |
Note: The table above highlights the largest positions by value. The filing lists multiple entries for MKS Instruments which have been combined for clarity.
Material Changes and Portfolio Focus
As this is a snapshot of holdings at a specific date, the filing does not provide comparative data against the prior quarter (March 31, 2023) to determine material changes in position size or new entries/exits. The portfolio demonstrates a heavy concentration in:
- Technology & Software: ZoomInfo Technologies, Vitru Ltd, Getty Images.
- Biotechnology & Pharmaceuticals: Adicet Bio, Effector Therapeutics, Jasper Therapeutics, Phathom Pharmaceuticals, and others.
- Real Estate & Services: Invitation Homes, CubeSmart, Seacor Marine Holdings.
Guidance, Risks, and Contingencies
This Form 13F filing does not contain management commentary, forward-looking guidance, risk factors, or contingency disclosures. It is a regulatory disclosure of asset ownership only. The filing includes a standard disclaimer that the SEC has not reviewed the information for accuracy or completeness.
Key Facts for Investor Verification
- Top Holdings: Verify the valuation of the two largest positions, Quidelortho Corp (~$1.03B) and ZoomInfo Technologies (~$931M), which represent a significant portion of the reported equity value.
- Concentration Risk: Assess the exposure to the biotechnology sector, which comprises a large number of the listed positions (e.g., Adicet Bio, Effector Therapeutics, Jasper Therapeutics).
- Voting Control: Confirm that Carlyle Group Inc. holds "Sole" voting authority for all listed positions, indicating direct control over these specific equity stakes.
- Missing Data: Note that this filing does not disclose Carlyle Group's own operating revenue, debt levels, or liquidity position; those metrics must be sourced from the company's 10-Q or 10-K filings.